Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
Inv. presentation

Eliem Therapeutics, Inc. (ELYM) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/20/2023 8-K Quarterly results
05/19/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/11/2023 8-K Quarterly results
Docs: "Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights Presented initial preclinical data from ETX-123, Eliem's lead Kv7 program candidate, demonstrating a promising profile and confirming the proposed mechanism of action on neuronal excitability Additional preclinical data updates for ETX-123 expected in 2023 SEATTLE and CAMBRIDGE, UK, -- – May 11, 2023 – Eliem Therapeutics, Inc. , a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter ended March 31, 2023. “We were excited to share our initial preclinical ...",
"Clinical Stage Neurology Company Focused on Neuronal Excitability Disorders Corporate Presentation"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/06/2023 ARS Form ARS - Annual Report to Security Holders:
04/06/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/06/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/21/2023 3 Pimblett Emily (Chief Accounting Officer) has filed a Form 3 on Eliem Therapeutics, Inc.
03/16/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/14/2023 4 Morisset Valerie (EVP, R&D and CSO) has filed a Form 4 on Eliem Therapeutics, Inc.
Txns: Exercised 255,219 options to buy @ $0.002, valued at $510.4
Exercised 61,191 options to buy @ $0.0002, valued at $12.2
03/08/2023 SC 13G/A Intermediate Capital Group plc reports a 7.5% stake in Eliem Therapeutics, Inc.
03/06/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/06/2023 8-K Quarterly results
Docs: "Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel opener program Implemented corporate reorganization and pipeline reprioritization extending cash runway into 2027 SEATTLE and CAMBRIDGE, UK, -- – March 6, 2023 – Eliem Therapeutics, Inc. , a biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter and year ended December 31, 2022. “We are excited to advance our Kv7 program forward with ETX-123 as..."
03/06/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A SAMLYN CAPITAL, LLC reports a 0% stake in Eliem Therapeutics, Inc.
02/08/2023 SC 13G/A BML Investment Partners, L.P. reports a 7.1% stake in Eliem Therapeutics, Inc.
01/24/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
12/20/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
Docs: "Eliem Therapeutics Reports Third Quarter Financial and Business Highlights Positioned to initiate ETX-155 Phase 2a trial in major depressive disorder in the first quarter of 2023 with 60-milligram dose Progressing IND-enabling studies for two Kv7 pre-candidates with safety studies planned in the first quarter of 2023 Cash runway expected to fund operations into 2025 SEATTLE and CAMBRIDGE, UK, -- – November 14, 2022 – Eliem Therapeutics, Inc. , a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today provided a business update and reported financial results for the quarter ended September 30, 2022. &#x2...",
"2 NO FOOD EFFECT3 ETX-155"
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/02/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/02/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/02/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/02/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/05/2022 8-K Quarterly results
09/22/2022 SC 13G ICG Life Sciences SCSp reports a 7.5% stake in Eliem Therapeutics, Inc.
08/15/2022 8-K Quarterly results
08/15/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/18/2022 8-K Quarterly results
06/01/2022 4 Tate Simon (Director) has filed a Form 4 on Eliem Therapeutics, Inc.
Txns: Granted 10,000 options to buy @ $3.46, valued at $34.6k
06/01/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/01/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/01/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy